Key result
The FMDV 2A peptide enables the coordinated co-expression of up to four proteins from a single vector, offering a more balanced and compact alternative to internal ribosomal entry sites.
Comparison
2A "CHYSEL" technology (FMDV 2A peptide) vs Internal ribosomal entry sites (IRESs)
Design
Review
Authors
Loading...
Supports compact multi-gene vectors in gene therapy research; leaves open clinical translation and safety validation.
The 2A peptide provides a compact and efficient alternative to IRESs for co-expressing multiple proteins from a single vector in gene therapy applications.
Pablo de Felipe (2004) conducted a review in Multi-gene diseases requiring gene therapy. FMDV 2A "CHYSEL" technology vs. Internal ribosomal entry sites (IRESs) was evaluated. The FMDV 2A peptide enables the coordinated co-expression of up to four proteins from a single vector, offering a more balanced and compact alternative to internal ribosomal entry sites.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: